Literature DB >> 20410679

High regression rate of coronary aneurysms developed in patients with immune globulin-resistant Kawasaki disease treated with steroid pulse therapy.

Shinya Adachi1, Heima Sakaguchi, Takashi Kuwahara, Yasushi Uchida, Toshiyuki Fukao, Naomi Kondo.   

Abstract

Kawasaki disease is an acute vasculitis syndrome of unknown etiology that mainly affects small and medium-size arteries, particularly the coronary artery. Coronary artery lesions may develop into aneurismal formation and thrombotic occlusion, and progress to ischemic heart disease. The aim of the present study was to investigate the effect of steroid pulse therapy following intravenous immune globulin (IVIG) treatment on the regression rate of aneurysms in Kawasaki disease. Among 93 sequential patients referred to us, because of coronary artery lesions in the acute phase, we found 23 aneurysms in 12 patients during the period from January 1997 to January 2008. We divided them into two groups: a non-steroid group, 7 patients (13 aneurysms) treated with single or multiple IVIG but no steroid pulse therapy; and a steroid group, 5 patients (10 aneurysms) treated with multiple IVIG followed by steroid pulse therapy. We compared the regression rate of the aneurysms between the two groups, retrospectively. The regression rates of the aneurysms in the steroid group were significantly higher than those in the non-steroid group when we analyzed 1) all aneurysms (p = 0.007), 2) giant aneurysms (aneurismal diameter was 4 or more x normal, or > 8 mm) (p = 0.018), and 3) aneurysms in IVIG-resistant patients who were resistant to initial IVIG therapy (p = 0.035). All aneurysms, including the giant aneurysms in the steroid group, regressed, and the regression rate of the aneurysms in the non-steroid group was about 46%(6/13). Steroid pulse therapy may be beneficial for IVIG-resistant patients. Our data suggest that steroid pulse therapy may lead to regression of aneurysms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20410679     DOI: 10.1620/tjem.220.285

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  9 in total

Review 1.  Treatment Options for Resistant Kawasaki Disease.

Authors:  Linny Kimly Phuong; Nigel Curtis; Peter Gowdie; Jonathan Akikusa; David Burgner
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

Review 2.  Kawasaki disease: etiopathogenesis and novel treatment strategies.

Authors:  Shreya Agarwal; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2016-09-13       Impact factor: 4.473

Review 3.  Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk.

Authors:  Durga Prasanna Misra; Sajjan N Shenoy
Journal:  Rheumatol Int       Date:  2016-02-17       Impact factor: 2.631

4.  Hypertension triggers the rupture of coronary artery aneurysm in an 8-year-old boy with Kawasaki disease.

Authors:  Peng Hu; Jun Wang; Xiao Chen Fan; Bo Hu; Ling Lu
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-08-16       Impact factor: 3.738

5.  Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas.

Authors:  Fernanda Falcini; Serena Capannini; Donato Rigante
Journal:  Pediatr Rheumatol Online J       Date:  2011-07-20       Impact factor: 3.054

6.  Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease.

Authors:  Kei Takahashi; Toshiaki Oharaseki; Tomokazu Nagao; Yuki Yokouchi; Hitomi Yamada; Noriko Nagi-Miura; Naohito Ohno; Tsutomu Saji; Tomio Okazaki; Kazuo Suzuki
Journal:  Pediatr Rheumatol Online J       Date:  2011-09-29       Impact factor: 3.054

7.  Risk Factors for Resistance to Intravenous Immunoglobulin Treatment and Coronary Artery Abnormalities in a Chinese Pediatric Population With Kawasaki Disease: A Retrospective Cohort Study.

Authors:  Jie Liu; Yanyun Huang; Cheng Chen; Danyan Su; Suyuan Qin; Yusheng Pang
Journal:  Front Pediatr       Date:  2022-04-20       Impact factor: 3.569

8.  Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.

Authors:  Jie Liu; Bingbing Ye; Danyan Su; Suyuan Qin; Weiying Zhao; Yusheng Pang
Journal:  Clin Rheumatol       Date:  2022-09-21       Impact factor: 3.650

9.  Etanercept suppresses arteritis in a murine model of kawasaki disease: a comparative study involving different biological agents.

Authors:  Ryuji Ohashi; Ryuji Fukazawa; Makoto Watanabe; Hanako Tajima; Noriko Nagi-Miura; Naohito Ohno; Shinichi Tsuchiya; Yuh Fukuda; Shunichi Ogawa; Yasuhiko Itoh
Journal:  Int J Vasc Med       Date:  2013-03-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.